Short Interest in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) Declines By 2.0%

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 1,189,611 shares, a decrease of 2.0% from the October 15th total of 1,214,174 shares. Approximately 3.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 21,451 shares, the days-to-cover ratio is presently 55.5 days.

In other news, Director James Lebar sold 200,000 shares of the company’s stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $2.15, for a total transaction of $430,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. 57.28% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp purchased a new stake in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the 2nd quarter valued at about $144,000. Bank of New York Mellon Corp bought a new position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the 2nd quarter valued at about $160,000. Schwab Charles Investment Management Inc. bought a new position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the 2nd quarter valued at about $167,000. BlackRock Inc. grew its holdings in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 9.4% during the 3rd quarter. BlackRock Inc. now owns 1,727,098 shares of the company’s stock valued at $3,230,000 after purchasing an additional 147,828 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 6,107.1% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 12,079,080 shares of the company’s stock valued at $27,178,000 after purchasing an additional 11,884,480 shares during the last quarter. Hedge funds and other institutional investors own 15.79% of the company’s stock.

Shares of NYSE ZOM opened at $1.78 on Friday. Zomedica Pharmaceuticals Corp has a 12-month low of $1.36 and a 12-month high of $2.98.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last announced its earnings results on Thursday, August 9th. The company reported ($0.04) earnings per share (EPS) for the quarter. As a group, equities research analysts forecast that Zomedica Pharmaceuticals Corp will post -0.11 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Short Interest in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) Declines By 2.0%” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/11/short-interest-in-zomedica-pharmaceuticals-corp-nyseamerican-zom-declines-by-2-0.html.

About Zomedica Pharmaceuticals Corp (NYSEAMERICAN)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

See Also: Price to Earnings Ratio (PE) Basics

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply